Genomics and proteomics in cancer

European Journal of Cancer

Volumn 39, Issue 9, 2003, Pages 1199-1215

  Baak, J P A ^a,b   Path, F R C ^a,b   Hermsen, M A J A ^c   Meijer, G ^c   Schmidt, J ^d   Janssen, E A M ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Competence Ctr Bio Molecular T ^*  (Austria)

Author keywords

Cancer; CGH; Chromosomal instability; Cytogenetics; DNA repair; FISH; Genomics; MSI; PCR; Proteomics; SKY

Indexed keywords

ALPHA INTERFERON; CADHERIN; CARRIER PROTEIN; COMPLEMENTARY DNA; CYCLIN D2; CYTOCHROME P450; DNA; ENDOTHELIN A RECEPTOR; ENTACTIN; GALACTOSIDE; GALECTIN; GRANULYSIN; HISTAMINE METHYLTRANSFERASE; INTERFERON REGULATORY FACTOR 2; LECTIN; ONCOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; POLYPEPTIDE; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR;

CANCER; CANCER GENETICS; CANCER GROWTH; CHROMOSOME DISORDER; COST EFFECTIVENESS ANALYSIS; DNA REPAIR; ENDOMETRIUM HYPERPLASIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION SYSTEM; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC CODE; GENETIC STABILITY; GENOMICS; HETEROZYGOSITY LOSS; HUMAN; HUMAN GENOME; KARYOTYPING; MICROSATELLITE INSTABILITY; MOLECULAR BIOLOGY; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SOLID TUMOR;

EID: 0037903488     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00265-X     Document Type: Review

References (112)

1. Casperson T.O. History of the development of cytophotometry from 1935 to the present. Anal. Quant. Cytol. Histol. 9:1987;2-5.
2. Merlo A., Herman J.G., Mao L.et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1:1995;686-692.
3. Hendrich B., Bird A. Jones P.A., Vogt P.K. Current Topics in Microbiology and Immunology, vol. 249, DNA Methylation and Cancer. 2000;170 Springer-Verlag, Berlin.
4. Klochendler-Yeivin A., Yaniv M. Chromatin modifiers and tumour suppression. Biochim. Biophys. Acta. 1551:2001;M1-10.
5. Baak JPA, Vooijs GP, Brugal G, Burger G. Nuclear image cytometry: quantitation of chromatin pattern, steroid receptor content and Ki-67. In Baale JPA, Ed. Manual of Quantitative Pathology in Cancer Diagnosis and Prognosis. Springer-Verlag, Heidelberg, 1991, 232-243.
6. Palcic B., Garner D.M., MacAulay C.E. Image cytometry and chemoprevention in cervical cancer. J. Cell. Biochem. 23(Suppl.):1995;43-54.
7. Mommers E.C., Poulin N., Sangulin J., Meijer C.J., Baak J.P., van Diest P.J. Nuclear cytometric changes in breast carcinogenesis. J. Pathol. 193:2001;33-39.
8. Offit K., Wong G., Filippa D.A., Tao Y., Chaganti R.S.K. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma, clinical correlations. Blood. 77:1991;1508-1915.
9. Mitelman F., Johansson B., Mandahl N., Mertens F. Clinical significance of cytogenetic findings in solid tumours. Cancer Genet. Cytogenet. 95:1997;1-8.
10. Knudson A.G.J.r. Mutation and cancer, Statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA. 68:1971;820-823.
11. Kinzler K.W., Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature. 386:1997;761-763.
12. Cahill D.P., Kinzler K.W., Vogelstein B., Lengauer C. Genetic instability and darwinian selection in tumours. Trends Cell. Biol. 9:1999;57-60.
13. Fearon E.R., Vogel stein B. A genetic model for colorectal tumourigenesis. Cell. 61:1990;759-767.
14. Forastiere A., Koch .W, Trotti A., Sidransky D. Head and neck cancer. N. Engl. J. Med. 345:2001;1890-1900.
15. Schwarz E., Freese U.K., Gissmann L.et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature. 314:1985;111-114.
16. Sakurazawa N., Tanaka N., Onda M., Esumi H. Instability of X chromosome methylation in aberrant crypt foci of the human colon. Cancer Res. 60:2000;3165-3169.
17. Zarbl H., Sukumar S., Arthur A.V., Martin-Zanca D., Barbacid M. Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-ethylurea during initiation of mammary carcinogenesis in rats. Nature. 315:1985;382-385.
18. Stoler D.L., Chen N., Basik M.et al. The onset and extent of genomic instability in sporadic colorectal tumour progression. Proc. Natl. Acad. Sci. USA. 96:1999;15121-15126.
19. Rowley J.D. Chromosome translocations, dangerous liaisons revisited. Nature Rev. Cancer. 1:2001;245-250.
20. Jallepalli P.V., Lengauer C. Chromosome segregation and cancer, cutting through the mystery. Nature Rev. Cancer. 1:2001;109-117.
21. Kallioniemi A., Kallioniemi O.P., Sudar D.et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumours. Science. 258:1992;818-821.
22. Ried T., Knutzen R., Steinbeck R.et al. Comparative genomic hybridization reveals a specific pattern of chromosomal gains and losses during the genesis of colorectal tumours. Genes, Chromosomes Cancer. 15:1996;234-245.
23. Meijer G.A., Hermsen M.A.J.A., Baak J.P.A.et al. Progression from colorectal adenoma to carcinoma is associated with non-random chromosomal gains as detected by CGH. J. Clin. Pathol. 51:1998;901-909.
24. Bardi G., Sukhikh T., Pandis N., Fenger C., Kronborg O., Heim S. Karyotypic characterization of colorectal adenocarcinomas. Genes Chromosomes Cancer. 12:1995;97-109.
25. Shih I.M., Zhou W., Goodman S.N., Lengauer C., Kinzler K.W., Vogelstein B. Evidence that genetic instability occurs at an early stage of colorectal tumourigenesis. Cancer Res. 61:2001;818-822.
26. Ried T., Heselmeyer-Haddad K., Blegen H., Schrock E., Auer G. Genomic changes defining the genesis, progression, and malignancy potential in solid human tumours, a phenotype/genotype correlation. Genes Chromosomes Cancer. 25:1999;195-204.
27. Redon R., Muller D., Caulee K., Wanherdrick K., Abecassis J., du Manoir S. A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas, PIK3CA but not p63 gene as a likely target of 3q26-qter gains. Cancer Res. 61:2001;4122-4129.
28. Ellis N.A., German J. Molecular genetics of Bloom's syndrome. Hum. Mol. Genet. 5:1996;1457-1463.
29. Bootsma D., Kraemer K.H., Cleaver J.E., Hoeijmakers J.H.J. Nucleotide excision repair syndromes, Xeroderma pigmentosa, Cockayne Syndrome, and trichothiodystrophy. Vogelstein B., Kinzler K.W. The Molecular Basis of Cancer. 1998;245-274 McGraw-Hill, New York.
30. Joenje H., Patel K.J. The emerging genetic and molecular basis of Fanconi Anaemia. Nature. 2:2001;446-457.
31. Marra G., Boland C.R. Hereditary nonpolyposis colorectal cancer, the syndrome, the genes, and historical perspectives. J. Natl. Cancer Inst. 87:1995;1114-1125.
32. Newsham I.F., Hadjistilianou T., Cavenee W.K. Retinoblastoma. Vogelstein B., Kinzler K.W. The Molecular Basis of Cancer. 1998;367-392 McGraw-Hill, New York.
33. Malkin D. p53 and the Li-Fraumeni syndrome. Biochim. Biophys. Acta. 1198:1994;197-213.
34. Kamb A., Herlyn M. Malignant melanoma. Vogelstein B., Kinzler K.W. The Molecular Basis of Cancer. 1998;507-518 McGraw-Hill, New York.
35. Couch F.J., Weber B.L. Breast cancer. Vogelstein B., Kinzler K.W. The Molecular Basis of Cancer. 1998;537-564 McGraw-Hill, New York.
36. Felsher D.W., Bishop J.M. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc. Natl. Acad. Sci. USA. 96:1999;3940-3944.
37. Duesberg P., Rausch C., Rasnick D., Hehlmann R. Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc. Natl. Acad. Sci. USA. 95:1998;13692-13697.
38. Fodde R., Kuipers J., Rosenberg C.et al. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat. Cell. Biol. 3:2001;433-438.
39. Kaplan K.B., Burds A.A., Swedlow J.R., Bekir S.S., Sorger P.K., Nathke I.S. A role for the adenomatous polyposis coli protein in chromosome segregation. Nat. Cell. Biol. 3:2001;429-432.
40. Abdel-Rahman W.M., Katsura K., Rens W.et al. Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement. Proc. Natl. Acad. Sci. USA. 98:2001;2538-2543.
41. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instabilities in human cancers. Nature. 396:1998;643-649.
42. Amon A. The spindle checkpoint. Curr. Opin. Genet. Dev. 9:1999;69-75.
43. Nigg E.A. Mitotic kinases as regulators of cell division and its checkpoints. Nat. Rev. Mol. Cell. Biol. 2:2001;21-32.
44. Nagahata T., Hirano A., Utada Y.et al. Correlation of allelic losses and clinicopathological factors in 504 primary breast cancers. Breast Cancer. 9:2002;208-215.
45. Murata H., Khattar N.H., Kang Y., Gu L., Li G.M. Genetic and epigenetic modification of mismatch repair genes hMSH2 and hMLH1 in sporadic breast cancer with microsatellite instability. Oncogene. 21:2002;5696-5703.
46. Hansemann D. Uber asymmetrische Zellteilung in Epithelkrebsen und deren biologischen bedeutung. Virchow's Arch. Path. Anat. 119:1890;299-326.
47. Tjio J.H., Levan A. The chromosome number of man. Hereditas. 42:1956;1-6.
48. Rowley J.D. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 243:1973;290-293.
49. Waters J.J., Barlow A.L., Gould C.P. Demystified . FISH. Mol. Pathol. 51:1998;62-70.
50. Hermsen M.A.J.A., Baak J.P.A., Weiss J.et al. Genetic analysis of 53 lymph node-negative breast carcinomas by CGH and relation to clinical, pathological, morphometric, and DNA cytometric prognostic factors. J. Pathol. 186:1998;356-362.
51. Janssen EAM, Baak JPA, Guervós MA, Diest PJ van, Jiwa M, Hermsen MAJA. Lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter and oestrogen receptor. J Pathol (in press).
52. Solinas-Toldo S., Lampel S., Stilgenbauer S.et al. Matrix-based comparative genomic hybridization. biochips to screen for genomic imbalances Genes Chromosomes Cancer. 20:1997;399-407.
53. Pinkel D., Segraves R., Sudar D.et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat. Genet. 20:1998;207-211.
54. Weiss M.M., Snijders A.M., Meijer G.A.et al. Microarray CGH reveals a narrow gain at 20q13 in human gastric carcinomas. Gastroenterology. 120:2001;A1541.
55. Snijders A.M., Nowak N., Segraves R.et al. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat. Genet. 29:2001;263-264.
56. Hyman E., Kauraniemi P., Hautaniemi S.et al. Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res. 62:2002;6240-6245.
57. Schröck E., du Manoir S., Veldman T.et al. Multicolor spectral karyotyping of human chromosomes. Science. 273:1996;494-497.
58. Irizarry R.A., Bolstad B.M., Collin F., Cope L.M., Hobbs B., Speed T.P. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31:2003;E15.
59. Coller H.A., Grandori C., Tamayo P.et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signalling, and adhesion. Proc. Natl. Acad. Sci. USA. 97:2000;3260-3265.
60. Golub T.R., Slonim D.K., Tamayo P.et al. Molecular classification of cancer, class discovery and class prediction by gene expression monitoring. Science. 286:1999;531-537.
61. Su Y.A., Bittner M.L., Chen Y.et al. Identification of tumor-suppressor genes using human melanoma cell lines UACC903, UACC903(+6), and SRS3 by comparison of expression profiles. Mol. Carcinog. 28:2000;119-127.
62. Maniotis A.J., Folberg R., Hess A.et al. Vascular channel formation by human melanoma cells in vivo and in vitro, vasculogenic mimicry [see comments]. Am. J. Pathol. 155:1999;739-752.
63. Brasier A.R. Retriever and CompareTable, two informatics tools for data analysis of high-density oligonucleotide arrays. Biotechniques. 32:2002;100-109.
64. Mutter G.L., Baak J.P.A., Fitzgerald J.et al. Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecol Oncol. 83:2001;177-185.
65. Pruitt K.D., Katz K.S., Sicotte H., Maglott D.R. Introducing RefSeq and LocusLink, curated human genome resources at the NCBI. Trends Genet. 16:2000;44-47.
66. Wheeler D.L., Chappey C., Lash A.E.et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 28:2000;10-14.
67. National Center for Biotechnology Information (USA). Locuslink [online]. Available: http,//www ncbi nlm nih gov/LocusLink/2000.
68. Mutter GL. Endometrial precancer type collection [online]. Available: http,//www.endometrium.org/2000.
69. Perou C.M., Sørlie T., Eisen M.B.et al. Molecular protraits of human breast tumours. Nature. 406:2000;747-752.
70. Hedenfalk I., Duggan D., Chen Y.et al. Gene-expression profiles in hereditary breast cancer. N. Eng. J. Med. 344:2001;539-548.
71. van 't Veer L.J., Dai H., van de Vijver M.J.et al. Expression profiling predicts outcome in breast cancer. Breast Cancer Res. 5:2002;57-58.
72. Gruvberger S., Ringner M., Chen Y.et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Research. 61:2001;5979-5984.
73. West M., Blanchette C., Dressman H.et al. Predicting the clinical status of human breast cancer by using gene expression profiles. PNAS. 98:2001;11462-11467.
74. Ahr A., Kam T., Solbach S.et al. Identification of high risk breast cancer by gene expression profiling. Lancet. 359:2002;131-132.
75. van de Vijver M.J., He Y.D., van't Veer L.J.et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347:2002;1999-2009.
76. Wilkins M.R., Sanchez J.C., Gooley A.A.et al. Progress with proteome projects. Why all proteins expressed by a genome should be identified and how to do it. Biotechnol. Genet. Eng. Rev. 13:1996;19-50.
77. Wilkins M.R., Sanchez J.C., Williams K.L., Hochstrasser D.F. Current challenges and future applications for protein maps and post-translational vector maps in proteome projects. Electrophoresis. 17:1996;830-838.
78. Reynolds T. For proteomics research, a new race has begun. J. Natl. Cancer Inst. 94:2002;552-554.
79. Anderson N.G., Anderson L. The Human Protein Index. Clin. Chem. 28:1982;739-748.
80. Paweletz C.P., Liotta L.A., Petricoin 3rd E.F. New technologies for biomarker analysis of prostate progression, laser capture microdissection and tissue proteomics. Urology. 57:2001;160-163.
81. Czerwenka K.F., Manavi M., Hosmann J.et al. Comparative analysis of two-dimensional protein patterns in malignant and normal human breast tissue. Cancer Detect. Prev. 25:2001;268-279.
82. Kuerer H.M., Golgknopf I.L., Fritsche H., Krishnamurthy S., Sheta E.A., Hunt K.K. Identification of distinct protein expression patterns in bilateral matched pair breast ductal fluid specimens from women with unilateral invasive breast carcinoma, High-throughput biomarker discovery. Cancer. 95:2002;2276-2282.
83. Fields S., Song O.-K. A novel genetic system to detect protein-protein interactions. Nature. 340:1989;245-246.
84. Coates P.J., Hall P.A. The yeast two hybrid system for identifying protein-protein interactions. J. Path. 199:2003;4-7.
85. Gavin A.C., Bosche M., Krause R.et al. Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature. 15:2002;141-147.
86. Schmidt M.H.H., Broll R., Bruch H.P., Bõlger O., Duchrow M. The proliferation marker pKI-67 organizes the nucleolus during the cell cycle depending on Ran and cyclin B. J. Path. 199:2003;18-27.
87. Schweitzer B. Multiplexed protein profiling on microarrays by rolling-circle amplification. Nat Biotechnol. 20:2002;359-365.
88. Haab B.B., Dunham M.J., Brown P.O. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol. 2:2001;0004.1-0004.13.
89. Paweletz C.P. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene. 20:2001;1981-1989.
90. Schmid J.A., Sitte H.H. Fluorescence resonance energy transfer in the study of cancer pathways. Curr. Op.in Onco.l. 15:2003;55-64.
91. Merchant M., Weinberger S.R. Recent advancements in surface-enhancement laser desorption/ionisation-time of flight-mass spectrometry. Electrophoresis. 21:2000;1164-1167.
92. Wright G.L. Jr., Cazares L.H., Leung S.-M.et al. Proteinchip® surface enhanced laser desorption/ionisation (SELDI) mass spectrometry, a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostate Dis. 2:1999;264-276.
93. Vlahou A., Schellhammer P.F., Medrinos S.et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am. J. Pathol. 158:2001;1491-1502.
94. Li J., Zhang Z., Rosenzweig J., Wang Y.Y., Chan D.W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 48:2002;1296-1304.
95. Petricoin III P.F., Ardekani A.M., Hitt B.A.et al. Use of proteomic patterns in serum to identify ovarian cancer. The Lancet. 359:2002;572-577.
96. Torhorst J., Bucher C., Kononen J.et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am. J. Path. 159:2001;2249-2256.
97. Zhang D., Salto-Tellez M., Choudary Putti T., Do E. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod. Pathol. 16:2003;79-85.
98. Poremba C., Heine B., Daillo R.et al. Telomerase as a prognostic marker in breast cancer, high-throughput tissue microarray analysis of hTERT and hTR. J. Path. 198:2002;181-189.
99. Camp R.L., Chung G.G., Rimm D.L. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nature Medicine. 11:2002;1323-1327.
100. Druker B.J. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol. Med. 8:2002;S14-AS8.
101. Mitelman F, Mertens F, Johansson B. A breakpoint map of recurrent chromosomal rearrangements in human neoplasia [special issue]. Nat Genet 1997, 417-472.
102. Funkhouser W.K., Kaiser-Rogers K. Review, Significance of, and optimal screening for, Her2/neu gene amplification and protein overexpression in breast cacinoma. Ann. Clin. Lab. Sci. 31:2001;349-358.
103. Halling K.C., King W., Sokolowa I.A.et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J. Urol. 164:2000;1768-1775.
104. Harris R.A., Yang A., Stein R.C.et al. Cluster analysis of an extensive human breast cell line protein expression map database. Proteomics. 2:2002;212-223.
105. Li J., Zhang Z., Rosenzweig J., Wang Y.Y., Chan D.W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 48:2002;1296-1304.
106. Petricoin III P.F., Ardekani A.M., Hitt B.A.et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 359:2002;572-577.
107. Fetsch P.A., Simone N.L., Brynat-Greenwood P.K.et al. Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry. Am. J. Clin. Path. 118:2002;870-876.
108. Camp R.L., Chung G.G., Rimm D.L. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 11:2002;1323-1327.
109. Gharbi S., Gaffney P., Yang A.et al. Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. Mol. Cell. Prot. 1:2002;91-98.
110. Adam PJ, Boyd R, Tyson KL, et al. Comprehensive proteomic analysis of breast cancer cell membrane reveals unique proteins with potential roles in clinical cancer. J Biol Chem 2003, 278, 6482-6489.
111. Baak J.P.A. Perspectives Editorial. the framework of pathology, good laboratory practice by quantitative and molecular methods J. Pathol. 198:2002;277-283.
112. Baak J.P.A., Ørbo A., Diest P.J.et al. Prospective multicenter evaluation of the morphometric D-Score for prediction of the outcome of endometrial hyperplasias. Am. J. Surg. Path. 25:2001;930-935.